 Primary Myelofibrosis
"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Descriptor ID |
D055728
|
| MeSH Number(s) |
C15.378.190.636.765
|
| Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Myelofibrosis
- Myelofibroses
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Fibrosis, Bone Marrow
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in this website by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 0 | 1 | 1 | | 1984 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 5 | 0 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 4 | 0 | 4 | | 2008 | 0 | 1 | 1 | | 2009 | 2 | 1 | 3 | | 2010 | 1 | 0 | 1 | | 2013 | 3 | 2 | 5 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles.
-
Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019 Aug 15; 25(16):4898-4906.
-
McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the Treatment of WHIM Syndrome. N Engl J Med. 2019 01 10; 380(2):163-170.
-
Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
-
Rein LA, Wisler JW, Kim J, Theriot B, Huang L, Price T, Yang H, Chen M, Chen W, Sipkins D, Fedoriw Y, Walker JK, Premont RT, Lefkowitz RJ. ß-Arrestin2 mediates progression of murine primary myelofibrosis. JCI Insight. 2017 12 21; 2(24).
-
Pettit K, Odenike O. Novel Therapies for Myelofibrosis. Curr Hematol Malig Rep. 2017 12; 12(6):611-624.
-
Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 03; 127(4):1316-1320.
-
Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137.
-
Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
-
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
-
Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|